Quality of life in ovarian cancer patients receiving maintenance therapy with bevacizumab versus PARPi: a network meta-analysis.

INTRODUCTION: Bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) administered as maintenance therapies after platinum-based chemotherapy have shown a progression-free survival benefit in patients with ovarian cancer. However, there is no…

Preview only. Read the full abstract at the source